Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Keeps "Neutral" Rating at HC Wainwright

Key Points

• HC Wainwright reiterated a “neutral” rating on EyePoint Pharmaceuticals, while analyst consensus remains “hold,” based on two buy, eight hold, and two sell ratings. The average analyst price target is $22.25.
• EyePoint shares opened at $0.44, near their 52-week low of $0.40 and well below the 52-week high of $19.11. The company has a market capitalization of approximately $37.9 million.
• The company reported a quarterly loss of $1.09 per share, missing estimates by $0.08, despite revenue of $510,000 exceeding expectations. Analysts expect a full-year loss of approximately $3.51 per share, while institutional investors own 99.41% of the stock.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report)'s stock had its "neutral" rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports.

Several other research firms have also issued reports on EYPT. Guggenheim lowered Eyepoint Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Monday. Citigroup reduced their price target on shares of Eyepoint Pharmaceuticals to $17.00 and set a "buy" rating on the stock in a research note on Tuesday, August 18th. Mizuho reaffirmed a "neutral" rating and set a $0.50 price target on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Sunday, September 27th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and set a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $22.25.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $0.44 on Tuesday. The business's 50 day simple moving average is $4.77 and its 200 day simple moving average is $10.30. Eyepoint Pharmaceuticals has a 1 year low of $0.40 and a 1 year high of $19.11. The company has a market capitalization of $37.93 million, a P/E ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. On average, sell-side analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. KBC Group NV bought a new position in Eyepoint Pharmaceuticals in the first quarter valued at about $29,000. Janney Montgomery Scott LLC grew its holdings in shares of Eyepoint Pharmaceuticals by 14.8% during the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company's stock worth $391,000 after purchasing an additional 3,900 shares during the last quarter. Baird Financial Group Inc. grew its holdings in shares of Eyepoint Pharmaceuticals by 16.4% during the second quarter. Baird Financial Group Inc. now owns 32,732 shares of the company's stock worth $468,000 after purchasing an additional 4,613 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $72,000. Finally, Pictet Asset Management Holding SA acquired a new position in shares of Eyepoint Pharmaceuticals in the first quarter valued at approximately $141,000. Institutional investors own 99.41% of the company's stock.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint plans to reduce operating expenses and concentrate resources on its late-stage DURAVYU program for DME. The narrower focus could extend the company’s cash runway and preserve value in its remaining lead program. EyePoint Announces Strategic Prioritization
• Neutral Sentiment: Unusual options activity included purchases of 7,885 call contracts, approximately 69% above typical daily call volume. This may indicate speculative interest or expectations of a rebound, but it does not change the company’s fundamental outlook.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. The setback led the company to halt related clinical trials early, removing a major potential catalyst and raising doubts about the drug’s commercial prospects in the market. EyePoint Announces Topline Results from LUCIA
• Negative Sentiment: The company announced a 53% workforce reduction as part of its restructuring after the clinical-trial setback. Although the cuts should lower expenses, they also signal a substantially reduced operating plan and weaker near-term growth prospects. EyePoint Pharmaceuticals to Cut 53% of Workforce
• Negative Sentiment: Guggenheim downgraded EYPT from “buy” to “neutral,” while Jefferies moved from “buy” to “hold.” Jefferies assigned a $1.00 price target, implying substantial upside from the current level, but the downgrade reflects sharply reduced confidence following the LUCIA results.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses. The inquiry adds legal and reputational risk, although it does not establish wrongdoing. EyePoint Pharmaceuticals Investigation Notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint's commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.